Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eledon Pharmaceuticals, Inc.

2.69
-0.0600-2.18%
Post-market: 2.690.00000.00%19:50 EDT
Volume:7.56M
Turnover:20.33M
Market Cap:161.08M
PE:-8.52
High:2.79
Open:2.77
Low:2.61
Close:2.75
Loading ...

Eledon Pharmaceuticals Announces R&D Day to Highlight Tegoprubart's Clinical Development in Transplantation

Reuters
·
26 Jun

Eledon Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
18 Jun

Eledon Pharmaceuticals Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $9

THOMSON REUTERS
·
18 Jun

Eledon Pharmaceuticals assumed with a Buy at H.C. Wainwright

TIPRANKS
·
18 Jun

Eledon Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
13 Jun

Eledon Pharmaceuticals (ELDN) Receives a Buy from Noble Financial

TIPRANKS
·
19 May

Eledon Pharma Q1 EPS $(0.08) Beats $(0.30) Estimate

Benzinga
·
15 May

Eledon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Eledon Pharmaceuticals Inc - on Track to Report Phase 2 Bestow Trial Results in Q4 2025

THOMSON REUTERS
·
15 May

Press Release: Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

Dow Jones
·
15 May

Eledon Pharmaceuticals Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
05 May

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has caught the attention of institutional investors who hold a sizeable 46% stake

Simply Wall St.
·
02 May

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
25 Mar

Guggenheim Remains a Buy on Eledon Pharmaceuticals (ELDN)

TIPRANKS
·
24 Mar

BRIEF-Eledon Pharmaceuticals FY Operating Expenses USD 70.577 Million

Reuters
·
21 Mar

Eledon Pharma FY 2024 GAAP EPS $(0.75) Misses $(0.64) Estimate

Benzinga
·
21 Mar

Eledon Pharmaceuticals: Proceeds From Oversubscribed $85 Million Underwritten Offering Extend Cash Runway to End of 2026

THOMSON REUTERS
·
21 Mar

Eledon Pharmaceuticals: Topline Results From Phase 2 Bestow Trial of Tegoprubart in Kidney Transplantation Expected in Fourth Quarter of 2025

THOMSON REUTERS
·
21 Mar

Eledon Pharmaceuticals FY Basic EPS USD -0.75

THOMSON REUTERS
·
21 Mar

Press Release: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Dow Jones
·
21 Mar